Literature DB >> 16155931

Faisalabad histiocytosis mimics Rosai-Dorfman disease: brothers with lymphadenopathy, intrauterine fractures, short stature, and sensorineural deafness.

Hans-Christoph Rossbach1, Carlos Dalence, Tung Wynn, Cameron Tebbi.   

Abstract

Rosai-Dorfman disease (RDD) is a rare, sporadic histiocytic disorder characterized by painless but protracted lymphadenopathy. Its etiology remains unclear. The observation of congenital disease and reports of familial cases with seven pairs of siblings including three sets of identical twins suggests a genetic predisposition in some patients with this condition. We now report two brothers of consanguineous Palestinian parents, whose lymphadenopathy, lymph node histology, and polyclonal hypergammaglobulinemia indicated RDD. The presence of intrauterine fractures, short stature, and sensorineural hearing impairment suggested a rare familial form of the disorder. Moynihan et al. recently described a Pakistani family with a familial histiocytic disorder highly reminiscent of the brothers reported here, whose lymph node morphology was apparently consistent with RDD as well. The presence of sensorineural deafness, short stature, and joint contractures, however, suggested a separate, rare autosomal recessive syndrome referred to as Faisalabad histiocytosis, after the family's place of origin. We believe that the brothers described here represent a second family with Faisalabad histiocytosis, which mimics RDD histologically. Copyright (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2006        PMID: 16155931     DOI: 10.1002/pbc.20605

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  7 in total

1.  Accelerated coronary atherosclerosis and H syndrome.

Authors:  Ravindranath K Shankarappa; Rajiv Ananthakrishna; Ravi S Math; Sachin Dhareppa Yalagudri; Satish Karur; Ramesh Dwarakaprasad; Manjunath C Nanjappa; Vered Molho-Pessach
Journal:  BMJ Case Rep       Date:  2011-10-04

Review 2.  Histiocytic disorders.

Authors:  Kenneth L McClain; Camille Bigenwald; Matthew Collin; Julien Haroche; Rebecca A Marsh; Miriam Merad; Jennifer Picarsic; Karina B Ribeiro; Carl E Allen
Journal:  Nat Rev Dis Primers       Date:  2021-10-07       Impact factor: 65.038

3.  Mutations in SLC29A3, encoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and familial Rosai-Dorfman disease.

Authors:  Neil V Morgan; Mark R Morris; Hakan Cangul; Diane Gleeson; Anna Straatman-Iwanowska; Nicholas Davies; Stephen Keenan; Shanaz Pasha; Fatimah Rahman; Dean Gentle; Maaike P G Vreeswijk; Peter Devilee; Margaret A Knowles; Serdar Ceylaner; Richard C Trembath; Carlos Dalence; Erol Kismet; Vedat Köseoğlu; Hans-Christoph Rossbach; Paul Gissen; David Tannahill; Eamonn R Maher
Journal:  PLoS Genet       Date:  2010-02-05       Impact factor: 5.917

4.  Identification of a novel mutation in solute carrier family 29, member 3 in a Chinese patient with H syndrome.

Authors:  Jia-Wei Liu; Nuo Si; Lian-Qing Wang; Ti Shen; Xue-Jun Zeng; Xue Zhang; Dong-Lai Ma
Journal:  Chin Med J (Engl)       Date:  2015-05-20       Impact factor: 2.628

Review 5.  A novel homozygous frame-shift mutation in the SLC29A3 gene: a new case report and review of literature.

Authors:  Sadaf Noavar; Samira Behroozi; Taraneh Tatarcheh; Farshid Parvini; Majid Foroutan; Hossein Fahimi
Journal:  BMC Med Genet       Date:  2019-08-29       Impact factor: 2.103

6.  Adult stem cell deficits drive Slc29a3 disorders in mice.

Authors:  Sreenath Nair; Anne M Strohecker; Avinash K Persaud; Bhawana Bissa; Shanmugam Muruganandan; Craig McElroy; Rakesh Pathak; Michelle Williams; Radhika Raj; Amal Kaddoumi; Alex Sparreboom; Aaron M Beedle; Rajgopal Govindarajan
Journal:  Nat Commun       Date:  2019-07-03       Impact factor: 14.919

7.  H Syndrome: Report of The First Case in African Ethnicity.

Authors:  Osama Khder Ahmed Elmansour; Ahmed Osama Ahmed Babikir
Journal:  Cureus       Date:  2022-03-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.